Prothena Corp Public LTD CO PRTA
We take great care to ensure that the data presented and summarized in this overview for PROTHENA CORP PUBLIC LTD CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRTA
View all-
Black Rock Inc. New York, NY3.86MShares$29.1 Million0.0% of portfolio
-
Adar1 Capital Management, LLC Austin, TX3.38MShares$25.4 Million3.14% of portfolio
-
Armistice Capital, LLC New York, NY2.24MShares$16.9 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.18MShares$16.4 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA1.27MShares$9.61 Million1.75% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA1.18MShares$8.91 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.15MShares$8.65 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.02MShares$7.68 Million0.01% of portfolio
-
State Street Corp Boston, MA1.01MShares$7.58 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX962KShares$7.26 Million0.0% of portfolio
Latest Institutional Activity in PRTA
Top Purchases
Top Sells
About PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Insider Transactions at PRTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 28
2025
|
Gene G. Kinney President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
140,000
+47.82%
|
-
|
|
Jul 28
2025
|
Michael J Malecek Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+50.0%
|
-
|
|
Jul 28
2025
|
Tran Nguyen Chief Strategy Officer and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
95,000
+49.43%
|
-
|
|
Jul 28
2025
|
Brandon S. Smith Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+50.0%
|
-
|
|
Jul 28
2025
|
Chad J. Swanson Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
-
|
|
Jul 28
2025
|
Karin L Walker Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Jul 28
2025
|
Wagner M. Zago Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
-
|
|
May 06
2025
|
Eco R1 Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,984,053
-27.22%
|
$13,888,371
$7.64 P/Share
|
|
May 05
2025
|
Eco R1 Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
977,693
-11.83%
|
$7,821,544
$8.11 P/Share
|
|
May 02
2025
|
Eco R1 Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,317,938
-28.64%
|
$26,543,504
$8.36 P/Share
|
|
Jan 15
2025
|
William P Scully |
SELL
Bona fide gift
|
Indirect |
12,000
-20.34%
|
-
|
|
Jan 14
2025
|
William P Scully |
BUY
Open market or private purchase
|
Direct |
100,000
+11.96%
|
$1,200,000
$12.79 P/Share
|
|
Jan 03
2025
|
William P Scully |
SELL
Bona fide gift
|
Direct |
1,000
-0.16%
|
-
|
|
Jan 02
2025
|
William P Scully |
SELL
Bona fide gift
|
Direct |
13,200
-2.03%
|
-
|
|
Dec 31
2024
|
William P Scully |
BUY
Open market or private purchase
|
Direct |
32,000
+1.58%
|
$416,000
$13.25 P/Share
|
|
Dec 20
2024
|
William P Scully |
SELL
Bona fide gift
|
Indirect |
40,000
-40.4%
|
-
|
|
Dec 20
2024
|
William P Scully |
SELL
Bona fide gift
|
Direct |
500
-0.08%
|
-
|
|
Dec 20
2024
|
William P Scully |
BUY
Open market or private purchase
|
Direct |
2,000
+0.32%
|
$30,000
$15.91 P/Share
|
|
Dec 19
2024
|
William P Scully |
SELL
Bona fide gift
|
Direct |
681,000
-52.48%
|
-
|
|
Dec 18
2024
|
William P Scully |
BUY
Open market or private purchase
|
Direct |
73,436
+5.36%
|
$954,668
$13.93 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 640K shares |
|---|---|
| Bona fide gift | 430K shares |
| Open market or private purchase | 207K shares |
| Open market or private sale | 6.28M shares |
|---|---|
| Bona fide gift | 748K shares |